A BBB-penetrating form of etanercept could be an important new drug for the treatment of AD, since tumor necrosis factor (TNF)α plays a role in the chronic neuro-inflammation of AD [123], as well as other neurodegenerative diseases, such as PD [124]. Here, TNF is linked to Parkinson disease.